Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Neerav Shukla, MD, Cynthia Wetmore, MD PhD, Maureen M O'Brien, MD, Lewis B. Silverman, MD, Patrick Brown, MD, Todd M Cooper, DO, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Ben Suttle, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2016) 128 (22): 2780.

https://doi.org/10.1182/blood.V128.22.2780.2780

Published: 2016

Journal Articles

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Eytan M. Stein, MD, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Raoul Tibes, MD PhD, Jesus G. Berdeja, MD, Mojca Jongen-Lavrencic, MD PhD, Jessica K. Altman, MD, Hartmut Dohner, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Greg Fine, MS, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Bob Lowenberg, MD PhD, Martin S Tallman, MD

Blood (2015) 126 (23): 2547.

https://doi.org/10.1182/blood.V126.23.2547.2547

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Vincent Ribrag, Jean-Charles Soria, Professor, Jean-Marie Michot, Anna Schmitt, MD, Sophie Postel-Vinay, MD, Fontanet Bijou, MD, Blythe Thomson, MD, Heike Keilhack, PhD, Stephen J. Blakemore, PhD, Larisa Reyderman, PhD, Pavan Kumar, PhD, Greg Fine, MS, Alice McDonald, Peter T Ho, PhD MD, Antoine Italiano, MD

Blood (2015) 126 (23): 473.

https://doi.org/10.1182/blood.V126.23.473.473

Published: 2015

Journal Articles

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Blood (2014) 124 (21): 387.

https://doi.org/10.1182/blood.V124.21.387.387

Published: 2014

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

Journal Articles

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

Nigel J Waters, PhD, Blythe Thomson, MD, Iain Gardner, PhD, Trevor N Johnson, PhD, Edward J Olhava, PhD, Roy M Pollock, PhD, Michelle Legler, MSHS, Robert A Copeland, PhD, Eric E Hedrick, MD

Blood (2014) 124 (21): 3619.

https://doi.org/10.1182/blood.V124.21.3619.3619

Published: 2014

Journal Articles

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Jessica Pollard, MD, Bill H Chang, MD, PhD, Todd Michael Cooper, Thomas Gross, MD, PhD, Sumit Gupta, MD, Phoenix A. Ho, MD, Suzanne M. McGoldrick, MD, Tanya C. Watt, MD, MSc, India Sisler, MD, Blythe Thomson, MD, Ann E Woolfrey, MD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 3969.

https://doi.org/10.1182/blood.V122.21.3969.3969

Published: 2013

Journal Articles

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Todd Michael Cooper, Jemily Malvar, M.S., Jeannette Cassar, Elena Eckroth, CCRC, Richard Sposto, PhD, Paul Gaynon, MD, Steven Dubois, MD, Lia Gore, MD, Margaret E. Macy, M.D., Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Javier Oesterheld, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2013) 122 (21): 624.

https://doi.org/10.1182/blood.V122.21.624.624

Published: 2013

Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2012) 120 (21): 3605.

https://doi.org/10.1182/blood.V120.21.3605.3605

Published: 2012

Journal Articles

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Nobuko Hijiya, MD, Jo-Anne Paul, Michael J. Borowitz, MD, PhD, Blythe Thomson, MD, Michael Isakoff, MD, Lewis B. Silverman, MD, Peter G Steinherz, MD, Richard Kadota, MD, Joseph G Pressey, MD, Violet Shen, MD, Roland Chu, MD, Todd Cooper, DO, Sima Jeha, MD, Bassem I. Razzouk, MD, Michael E. Rytting, MD, Elly Barry, MD, MMSc, William L. Carroll, MD, Paul Gaynon, MD

Blood (2010) 116 (21): 866.

https://doi.org/10.1182/blood.V116.21.866.866

Published: 2010

Journal Articles

Minimal Residual Disease Detected Prior to Transplantation Is Associated with Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia.

Jennifer H Foster, MD, MPH, Anne Woolfrey, MD, Brent Wood, MD, PhD, Blythe Thomson, MD

Blood (2008) 112 (11): 3246.

https://doi.org/10.1182/blood.V112.11.3246.3246

Published: 2008

Journal Articles

Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Nobuko Hijiya, MD, Paul S. Gaynon, MD, Manuel Fernandez, Lewis B. Silverman, MD, Blythe Thomson, MD, Roland Chu, Todd Cooper, DO, Richard Kadota, MD, Michael Rytting, M.D., Peter G. Steinherz, MD, Violet Shen, Sima Jeha, MD, Elly Barry, MD, William L. Carroll, MD

Blood (2008) 112 (11): 2925.

https://doi.org/10.1182/blood.V112.11.2925.2925

Published: 2008

Journal Articles

Participation in a Clinical Trial Does Not Impact Outcome in Pediatric Acute Lymphoblastic Leukemia

Carl Koschmann, MD, Doug S Hawkins, MD, Blythe Thomson, MD

Blood (2008) 112 (11): 1318.

https://doi.org/10.1182/blood.V112.11.1318.1318

Published: 2008

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

Nobuko Hijiya, MD, Paul Gaynon, MD, Manuel Fernandez, Michael Rytting, MD, Roland Chu, MD, Elly Barry, MD, Blythe Thomson, MD, Todd Cooper, MD, Richard Kadota, MD, Stanley Chaleff, MD, Peter Steinherz, MD, Rekha Abichandani, MD, William Carroll, MD

Blood (2007) 110 (11): 883.

https://doi.org/10.1182/blood.V110.11.883.883

Published: 2007

Journal Articles

A Successful Re-Induction Regimen for Relapsed Pediatric Acute Lymphoblastic Leukemia.

Jason Ackerman, Douglas Hawkins, MD, Karyn Brundige, ARNP, Laura Eisenberg, ARNP, Blythe Thomson, MD

Blood (2007) 110 (11): 863.

https://doi.org/10.1182/blood.V110.11.863.863

Published: 2007

NARROW

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Minimal Residual Disease Detected Prior to Transplantation Is Associated with Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia.

Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Participation in a Clinical Trial Does Not Impact Outcome in Pediatric Acute Lymphoblastic Leukemia

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

A Successful Re-Induction Regimen for Relapsed Pediatric Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only